Mustafa S Shahzad, Sokol Kristin
From the Rochester Regional Health, Rochester, New York.
University of Rochester School of Medicine and Dentistry; and.
J Food Allergy. 2024 Aug 1;7(1):7-13. doi: 10.2500/jfa.2025.7.250004. eCollection 2024 Aug.
Omalizumab is approved for the management of immunoglobulin E-mediated food allergy in individuals ages ≥ 1 year. Approval for food allergy followed the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) study, which demonstrated that omalizumab increases the threshold dose of multiple food allergens needed to elicit an allergic reaction. Despite the demonstrated efficacy in food allergy and favorable safety profile, many questions remain. This review addresses the efficacy of omalizumab for the management of food allergy, as monotherapy, and in conjunction with oral immunotherapy. Safety in children is paramount, and this review addresses noted adverse events of anaphylaxis and malignancy. There is minimal knowledge with regard to the real-world impact on food allergy-related quality of life. Many questions still remain, including identifying who is the ideal patient for omalizumab, determining the role of oral food challenges before and during therapy with omalizumab, evaluating food allergy tolerance while on treatment, and optimizing the cost-effectiveness of this efficacious and well-tolerated management option for food allergy.
奥马珠单抗被批准用于治疗≥1岁个体的免疫球蛋白E介导的食物过敏。食物过敏的批准是基于奥马珠单抗单药治疗以及在食物过敏参与者中作为多过敏原口服免疫治疗辅助治疗（OUtMATCH）的研究，该研究表明奥马珠单抗可提高引发过敏反应所需的多种食物过敏原的阈值剂量。尽管在食物过敏治疗中已证明其有效性且安全性良好，但仍存在许多问题。本综述探讨了奥马珠单抗作为单药治疗以及与口服免疫治疗联合使用时治疗食物过敏的疗效。儿童的安全性至关重要，本综述讨论了已注意到的过敏反应和恶性肿瘤等不良事件。关于其对食物过敏相关生活质量的实际影响的了解很少。许多问题仍然存在，包括确定谁是奥马珠单抗的理想患者、确定在奥马珠单抗治疗前和治疗期间进行口服食物激发试验的作用、评估治疗期间的食物过敏耐受性，以及优化这种对食物过敏有效且耐受性良好的治疗方案的成本效益。
